AKT is activated by phosphorylation at both Thr-308 and Ser-473 sites26, which activates downstream proteins to promote resistance to the EGFR inhibitor gefitinib in lung cancer patients27,28. This evidence concerns the gene AKT1 and lung carcinoma.